In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on United Therapeutics, with a price target of $500.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Thome has given his Buy rating due to a combination of factors surrounding United Therapeutics’ recent achievements and potential market opportunities. The company announced that its TETON-2 study met both primary and several secondary endpoints, which significantly reduces the risk associated with a supplemental New Drug Application (sNDA) filing. This development has been positively received by key opinion leaders, who are enthusiastic about the benefits and tolerability of the new agent, Tyvaso, which is poised to enter a multi-billion-dollar market.
Additionally, the TETON-2 study demonstrated a statistically significant improvement in forced vital capacity (FVC) for patients with idiopathic pulmonary fibrosis (IPF), surpassing expectations despite initial investor skepticism. The favorable safety profile of Tyvaso, along with its efficacy across various patient subgroups, positions it well against existing treatments. While questions remain about the full market potential and competition, the positive data from the study has de-risked a significant market opportunity for Tyvaso, leading to an optimistic outlook for UTHR shares.
According to TipRanks, Thome is an analyst with an average return of -0.2% and a 48.95% success rate. Thome covers the Healthcare sector, focusing on stocks such as Jazz Pharmaceuticals, PTC Therapeutics, and United Therapeutics.
In another report released on August 30, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $347.00 price target.